Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2426450
Max Phase: Preclinical
Molecular Formula: C31H42N2O9S
Molecular Weight: 618.75
Molecule Type: Small molecule
Associated Items:
ID: ALA2426450
Max Phase: Preclinical
Molecular Formula: C31H42N2O9S
Molecular Weight: 618.75
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COc1ccc(S(=O)(=O)N(CC(C)C)C[C@@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@@H]2COC[C@@H]3O[C@H]4OCC[C@H]4[C@@H]32)cc1
Standard InChI: InChI=1S/C31H42N2O9S/c1-20(2)16-33(43(36,37)23-11-9-22(38-3)10-12-23)17-26(34)25(15-21-7-5-4-6-8-21)32-31(35)42-28-19-39-18-27-29(28)24-13-14-40-30(24)41-27/h4-12,20,24-30,34H,13-19H2,1-3H3,(H,32,35)/t24-,25-,26+,27-,28+,29-,30+/m0/s1
Standard InChI Key: ZFMLVULNQHLHJT-PEIQIHAMSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 618.75 | Molecular Weight (Monoisotopic): 618.2611 | AlogP: 2.82 | #Rotatable Bonds: 12 |
Polar Surface Area: 132.86 | Molecular Species: NEUTRAL | HBA: 9 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 11 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 2 |
CX Acidic pKa: 13.50 | CX Basic pKa: | CX LogP: 3.17 | CX LogD: 3.17 |
Aromatic Rings: 2 | Heavy Atoms: 43 | QED Weighted: 0.37 | Np Likeness Score: 0.14 |
1. Ghosh AK, Parham GL, Martyr CD, Nyalapatla PR, Osswald HL, Agniswamy J, Wang YF, Amano M, Weber IT, Mitsuya H.. (2013) Highly potent HIV-1 protease inhibitors with novel tricyclic P2 ligands: design, synthesis, and protein-ligand X-ray studies., 56 (17): [PMID:23947685] [10.1021/jm400768f] |
Source(1):